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Partow Kebriaei,1 Rima Saliba,1 Gabriela Rondon,1 Alexandre Chiattone,1
Rajyalakshmi Luthra,2 Paolo Anderlini,1 Borje Andersson,1 Elizabeth Shpall,1 Uday Popat,1
Roy Jones,1 Laura Worth,3 Farhad Ravandi,4 Deborah Thomas,4 Susan O’Brien,4
Hagop Kantarjian,4 Marcos de Lima,1 Sergio Giralt,5 Richard Champlin1The introduction of tyrosine kinase inhibitors (TKI) has revolutionized therapy for patients with acute
lymphoblastic leukemia (ALL) who have the Philadelphia (Ph) chromosome. A retrospective analysis was
conducted on 102 adults and 11 children who received a first-matched related (n5 60), matched unrelated
(n 5 40), mismatched cord blood (n 5 12), or haploidentical (n 5 1) allogeneic hematopoietic stem cell
transplantation (HSCT) for Ph-positive (Ph1) ALL in first complete remission (n 5 71), second complete
remission (n 5 11), or with active disease (n 5 31) between 1990 and 2009. Sixty-seven patients received
TKI with upfront ALL therapy, and 32 patients received TKI maintenance following HSCT. With median
follow-up of 5 years among survivors (range: 1.1-20.4 years), overall survival (OS) was significantly better
for patients transplanted in first remission compared with HSCT in advanced disease: 43% versus 16%,
P 5 .002. Disease stage and age at time of HSCT, the development of acute graft-versus-host disease
(aGVHD), and decade of HSCT were found to significantly impact OS, progression-free survival (PFS),
and nonrelapse mortality (NRM) in multivariate analyses. Allogeneic HSCT provides durable remission
for patients with Ph1ALL in first remission. Neither TKI use pre- nor post-HSCTwere found to significantly
impact transplant outcomes in univariate and multivariate analyses.
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ALL that is more resistant to standard chemotherapy,
and disease-free survival using conventional chemother-
apy before imatinib use was reported to be 25% to 30%
in children [3] and\20% for adults [4]. Disease control
was significantly improved with the use of allogeneic
hematopoietic stem cell transplantation (HSCT) with
disease-free survival rates of 40% to 60%, and the
presence of the Ph-positive (Ph1) chromosome was a
primary indication for HSCT in first remission [5-7].
The Ph chromosome results from the reciprocal
translocation between chromosomes 9 and 22 that
fuses the breakpoint cluster region (BCR) gene on
chromosome 22 to the Ableson (ABL) gene on chromo-
some 9 [8,9]. The protein product of the fusion gene,
BCR-ABL, has enhanced tyrosine kinase activity
leading to the constitutive activation of a number of
downstream pro-proliferative and pro-survival signaling
pathways, and hence to leukemogenesis [10]. Imatinib
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Switzerland) binds the inactive moiety of the BCR-
ABL kinase, partially blocking its ATP binding site,
thereby preventing a conformational switch to the active
oncoprotein. The significant clinical activity and favor-
able toxicity profile of imatinib in Ph1 ALLwas evident
in initial phase I and II trials of the drug [11-13].
However, durable response was not seen with single
agent imatinib, but could be seen in combination
therapies. Despite relatively short follow-up and varia-
tions in chemotherapy schedules, it is clear that the incor-
poration of imatinib into the upfront treatment of these
patients results in higher response rates, an increased
number of transplant eligible patients and improved
event-free (EFS) and overall survival (OS) [14-17]. At
M.D. Anderson, the rate of allogeneic HSCT for
288 patients with Ph1 ALL treated between 1992
and 2000 with hyperCVAD (cyclophosphamide,
vincristine, doxorubicin) in the preimatinib era was
25% [4], compared with 33% reported for 54 patients
treated with hyerCVAD and imatinib between 2001
and 2006 [18]. However, this improvement in therapy
has generated significant questions in the management
of Ph1 ALL. First, some retrospective comparisons of
upfront therapy incorporating imatinib without alloge-
neicHSCT suggest thatHSCT for consolidation in first
remission may no longer be necessary [15], although
other reports indicate that the risk for relapse without
HSCT is increased with longer follow-up [18]. A pro-
spective, multicenter trial was developed by the South-
west Oncology Group and Blood and Marrow
Transplant Clinical Trials Network to investigate the
role of allogeneic HSCT in first remission in patients
with Ph1 ALL. This trial is currently accruing patients
andwill help to clarify this issue. Second, ifHSCT is still
indicated for these patients, will outcome be improved
with the use of TKI maintenance therapy following
HSCT? Several brief reports have reported on
the safety and feasibility of using imatinib asmaintenance
therapy following HSCT [19-21], but these small,
retrospective series were not designed to assess efficacy.
Thus, the role for TKI maintenance, and duration of
maintenance, is unclear. Finally, with the advent of
second- and third-generation TKI, the optimal TKI
for upfront therapy, and for maintenance following
HSCT, needs to be identified.
In this retrospective analysis, we report our long-
term outcomes of patients with Ph1 ALL who
received allogeneic HSCT, and investigate the impact
of TKI therapy both before and after HSCT.PATIENTS AND METHODS
Patients
The patient database at theM.D. Anderson Center
was screened for patients with the diagnosis ofPh1 ALL who received a first allogeneic HSCT
between August 1990 and June 2009. Patients were
treated on clinical trials that were approved by the
institutional review board, and written informed con-
sent was obtained in accordance with the Declaration
of Helsinki.
Donors
HLA typing for class I antigens was performed us-
ing serologic or low-resolution molecular techniques.
Low-resolution molecular typing using hybridization
techniques, followed by high-resolution molecular
typing using polymerase chain reaction, was per-
formed for class II alleles and as needed for selected
class I loci. After January 2002, high-resolutionmolec-
ular typing of class I and II antigens was performed for
all unrelated donor transplants. Peripheral blood pro-
genitor cells were obtained from donors using stan-
dard mobilization protocols and apheresis techniques
[22]; bone marrow was used if peripheral blood could
not be used. Progenitor cells from all related donors
were collected at the M.D. Anderson Cancer Center.
Bone marrow, peripheral blood, and cord blood pro-
genitor cells from unrelated donors were obtained
through the National Marrow Donor Program. All
grafts were T lymphocyte replete, except for the 1 pa-
tient who received a haploidentical graft.
Conditioning Regimens
Patients received a variety of myeloablative trans-
plant preparative regimens, based on available existing
protocols at time of treatment. Myeloablative,
radiation-based regimens were largely considered for
patients younger than 50 years of age, and included
cyclophosphamide (Cy) 60 mg/kg i.v. for 2 days,
followed by 12 Gy of total body irradiation (TBI)
administered in daily 3-Gy fractions through antero-
posterior fields, with partial lung shielding (5 half-
value layers) used during the third dose to reduce the
central axis dose by 76% to 83%, as previously
described (n 5 21) [23,24]. Additionally, Cy TBI was
combinedwith a singledose of etoposide at 1500mg/m2
(n 5 7) or thiotepa 5 mg/kg (n 5 9), or rituximab
375 mg/m2 weekly for 4 doses [25] (n5 11), or alemtu-
zumab10mg for5doses (n5 5). Sevenpatients received
a single dose of etoposide at 60 mg/kg 6 rituximab in
combination with 12 Gy TBI. Finally, 5 patients
received fludarabine (Flu) at 30mg/m2 daily for 4 doses
6melphalan (Mel) 140 mg/m2 followed by 9 to 12 Gy
TBI. One 59-year-old patient received a reduced inten-
sity radiation-based conditioning regimen consisting of
TBI 2 Gy combined with Flu at 40 mg/m2 daily for
4 doses followed by Cy 50 mg/kg.
Chemotherapy-only regimens included intrave-
nous busulfan (Bu) at 130 mg/m2 infused daily for
4 days, either as a fixed dose per body surface area, or
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5000 mmol-min determined by Bu test dose, followed
by 2 daily doses of Mel at 70 mg/m2 (n 5 20); oral Bu
at 4 mg/kg daily for 3 doses was combined with Cy
60 mg/kg for 2 doses (n 5 3), or thiotepa 250 mg/m2
for 3 doses (n 5 11) in transplants conducted during
the 1990s decade. Finally, Flu was administered at
25 mg/m2 daily  5 doses followed by 2 daily doses
of Mel at 70 mg/m2 6 single-dose thiotepa 10 mg/kg
(n 5 13).
TKI Use
Nearly all patients received TKIs as part of their
upfront therapy before HSCT since TKIs became
commercially available in 2001. The use of TKImainte-
nance followingHSCTwasphysician based, and admin-
istered as feasible for patients who were generally doing
well with adequate cell count recovery following trans-
plantation. For analyses purposes, we defined mainte-
nance use as TKI administered within the first 6
months following HSCT in the absence of disease.
Supportive Care
Graft-versus-host disease (GVHD) prophylaxis
consisted of a combination of tacrolimus and metho-
trexate 5 mg/m2 intravenously on days 1, 3, 6, and 11
after transplantation (n 5 93), tacrolimus, and steroid
(n 5 4), or cyclosporine and steroids or methotexate
(n 5 10). Cord blood recipients on the most recent
cord blood protocol received tacrolimus and mycofe-
nalate mofeteil 2 g per day from day 23 to day
100 (n5 5). The 1 patient with the haploidentical graft
did not receive any GVHD prophylaxis. Patients with
mismatched related or matched unrelated donors
additionally received antithymocyte globulin. Tacro-
limus levels were maintained at blood levels of 5 to
15 ng/mL and cyclosporine levels were kept at 150
to 300 ng/mL and tapered after 6 months at the dis-
cretion of the primary physician. Patients who experi-
enced grade II or higher acute GVHD (aGVHD)
received intravenous methylprednisolone at a dosage
of 2 mg/kg and, when possible, were enrolled in treat-
ment protocols for GVHD. Central nervous system
prophylaxis in the form of intrathecal cytarabine
administered monthly for 6 to 8 doses was recom-
mended only for patients receiving reduced-intensity
contitioning regimens, or for any patient with prior
history of central nervous system disease.
Institutional transplant guidelines for antimicro-
bial, antifungal, and antiviral prophylaxis were
followed. Specifically, prophylaxis consisted of tri-
methoprim and sulfamethoxazole for Pneumocystis
carinii and acyclovir or valacyclovir for herpes simplex
virus. Surveillance cytomegalovirus antigenemia test-
ing was performed for all patients, and a positive test
triggered the preemptive use of ganciclovir orfoscarnet. All patients received 5 mg/kg filgrastim
subcutaneously daily from day 17 until their absolute
neutrophil count was 0.5  109/L or higher for 3 con-
secutive days. Immunoglobulins at a dose of 200mg/kg
were infused weekly until day 100 following transplan-
tation in patients receiving unrelated donor grafts.
Packed red blood cells were administered to maintain
hemoglobin levels of 80 g/L (8 g/dL) or higher. Platelet
transfusions were administered to keep platelet counts
of 10  109/L or higher. All blood products were
filtered and irradiated.Definitions
Criteria for complete response included normal
cytogenetics, the absence of circulating blasts,\5%
marrow blasts, and a platelet count of 100  109/L
or higher. Standard morphologic criteria, conven-
tional cytogenetic analysis by G-banding, or both
were used to diagnose recurrent disease. The disease
phase at transplantation was defined using established
criteria. Response was documented as best response
occurring after day 30 following HSCT. Molecular
response measured by quantitative polymerase chain
reaction analysis for BCR-ABL rearrangement was
obtained when possible. Hematologic recovery was
defined on the date that the patient had an absolute
neutrophil count of 0.5 109/L or higher for 3 consec-
utive days. Platelet recovery was defined as occurring
on the first of 7 consecutive days with a platelet count
of 20  109/L or higher without transfusion support.
Failure to engraft by day130 and day142 was consid-
ered primary engraftment failure for patients receiving
adult stem cell grafts and umbilical cord blood grafts,
respectively. Hematopoietic chimerism was evaluated
in bone marrow by restriction fragment length
polymorphisms at the AY-29 or YNH24 loci, by
conventional cytogenetic analysis by G-banding, or
by fluorescence in situ hybridization studies in sex-
mismatched cases for the Y chromosome, to determine
donor engraftment.
OS was estimated from the time of HSCT until
death from any cause, and patients still alive at last
follow-up were censored at that point. Progression-
free survival (PFS) was estimated from HSCT until
the date of progression or death from any cause.
Patients alive and progression-free at last follow-up
were censored at that point. Nonrelapse mortality
(NRM) was defined as death from any cause other
than disease progression or relapse. The diagnosis of
GVHD was confirmed by biopsy when feasible but
was ultimately determined by clinical presentation.
Acute GVHD was clinically graded as 0 to IV based
on standard criteria [26]; chronic GVHD (cGVHD)
was classified as none, limited, or extensive [27]. Acute
GVHD, which persisted or progressed after day 100,
was also scored as cGVHD in this study.
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Cancer Institute Common Toxicity Criteria version
3.0 (Bethesda, MD). Adverse events and hematologic
parameters were monitored daily and clinical chemis-
try parameters at least twice weekly during the initial
hospitalization and then at increasing intervals up to
day 1100. Subsequently, patients were followed up
at least quarterly during the first year with physical
examinations, assessments for GVHD, blood counts,
and bone marrow aspiration and biopsy with chime-
rism analysis.Table 1. Patient and Treatment Characteristics
Patient Characteristics No. (%)
Total Patients, No. 113
TKI use
Pre-HSCT 67 (59)
Post-HSCT 32 (28)
None 43 (38)
Decade of HSCT
1990-1999 29 (26)
2000-2009 84 (74)
Median age at SCT in years (range) 37.5 (3-63)
Age up to 40 years 66 (58)
Age >40 years 47 (42)
Sex, male 58 (51)
Cytogenetics at diagnosis
Ph+ only 48 (42)
Ph+ others 50 (44)
unknown 15 (13)
WBC at presentation
Up to 30,000/mL 43 (38)Statistical Methods
The primary end points of this analysis were OS,
PFS, and NRM. The Kaplan-Meier method [28] was
used to esimate OS and PFS. The cumulative inci-
dence of NRM was estimated considering disease
progression as a competing risk. The cumulative inci-
dence of aGVHD and cGVHD was estimated consid-
ering death in the absence of GVHD as a competing
risk. Prognostic variables for OS, PFS, and NRM
including the use of TKI pre- or post-HSCT, were
evaluated on univariate and multivariate analysis using
Cox’s proportional hazards regression analysis [29].
Variables significant at the 0.1 level on univariate anal-
ysis were included in multivariate analysis to adjust for
potential confounding effects. A backward selection
procedure was used to determine the final predictive
model. The impact of TKI use post-HSCT was evalu-
ated in a landmark analysis starting at 6months follow-
ing HSCT. Only patients alive at that time point were
included in this analysis. All P values presented are
2 sided and statistical significance was determined at
the 5% level.Greater than 30,000/mL 48 (43)
Unknown 22 (19)
Time from Dx to HSCT, months (range) 6.2 (1.6-130.9)
CR1 patients, Pre-HSCT TKI 6.0 (2.1-26.6)
CR1 patients, No TKI 5.2 (1.9-13.7)
Disease status at HSCT
CR1 71 (63)
CR2 11 (10)
Active disease 31 (27)
Presence of MRD at HSCT, 83 evaluable
Yes 54 (65)
No 29 (35)
HSCT conditioning Rx
TBI-based 61 (54)
Non–TBI-based 52 (46)
GVHD prophylaxis
Tacrolimus-based 102 (90)
Cyclosporine-based 10 (9)
None 1 (1)
Donor type
Matched related 60 (53)
Matched unrelated 40 (35)
Haploidentical related 1 (1)
Mismatched cord blood 12 (11)
Stem cell source
Bone marrow 48 (42)
Peripheral blood 53 (47)
Cord blood 12 (11)
CR indicates complete remission; WBC, white blood cell.RESULTS
Patient and Treatment Characteristics
Patient demographics and baseline disease charac-
teristics are listed in Table 1. A total of 102 adults and
11 children, with a median age of 37.5 years (range:
3-63 years) were evaluated in this study. At time of
diagnosis, 42% of patients had only the Ph chromo-
some abnormality and 44% had additional cytogenetic
abnormalities. The majority of patients received their
transplant in the recent decade (74%). The median
time from diagnosis to transplantation was 6.2 months
(range: 1.6-130.9 months), with 73% of the patients in
remission at time of HSCT and 27% with active
disease at HSCT. Thirty-five percent of patients
were in molecular remission at time of HSCT. The
majority of patients received a matched related
(n 5 60) or matched unrelated donor (n 5 40)
HSCT (88%). Roughly equivalent numbers of bone
marrow (n5 48) and peripheral blood progenitor cells(n 5 53) were used as transplant cell sources. Twelve
patients received mismatched cord blood transplants.
The majority of patients received a myeloablative
preparative regimen (85%). Finally, the majority of
patients received tacrolimus and minidose methotrex-
ate for GVHD prophylaxis (90%).
Eighty-two patients were transplanted since 2000
when TKI became commercially available, and 67 of
these patients (82%) received TKI with their upfront
therapy, most commonly administered concurrently
with the hyperCVAD regimen [16,30]. Imatinib,
ranging in dose from 400 mg to 800 mg, was used in
62 patients. Eleven patients received dasatinib
ranging in dose from 50 mg to 140 mg. There was no
difference in time to HSCT between first remission
patients who received TKI before HSCT compared
with patients who did not receive TKI (Table 1).
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tients (39%) starting at a median of 2 months (range:
1-12 months) following HSCT; imatinib was the
TKI choice in all but 1 patient who received dasatinib
at 70 mg daily. Dasatinib was used for this patient’s
frontline therapy before HSCT, and the decision was
made to use the same TKI following HSCT. This
patient’s frontline therapy imatinib, at a median dose
of 300 mg (range: 100-800 mg), was continued for
a median of 10.6 months (range: 0.6-64 months) fol-
lowingHSCT. Themost common reason for stopping
TKI was completion of planned therapy at 1 year
following HSCT in the absence of disease, monitored
at the molecular level by polymerase chain reaction;
7 patients stopped TKI because of disease recurrence.
Among the remaining 19 patients who stopped TKI
for completion of planned therapy (n 5 11) or excess
toxicity (fluid retention n5 2, nausea n5 2, cytopenia
n 5 4), only 1 developed recurrence of disease at
a molecular level 3 years following stopping imatinib,
achieved another molecular remission with dasatinib,
and continues in molecular remission at 9.4 years fol-
lowing HSCT.
Response, Relapse, and Progression-free
Survival
Overall complete remission rate including both
bone marrow morphology and cytogenetic analysis
was 98% (n 5 103) of 105 evaluable patients. Seven
patients were not evaluable because of early death,
and 1 patient had autologous recovery following a re-
duced-intensity transplant conditioning regimen for
double cord blood transplantation, and remains alive
and in molecular remission on continued TKI therapy
at 1.6 years following HSCT. Among 69 patients who
had available molecular remission status pre- and
within 3 months following HSCT, 80% achieved orTable 2. Univariate Analysis of Significant Predictors for OS, PFS,
Variable
Overall Survival
HR (95% CI) P
WBC at Dx,  109/L (>30 versus #30) 0.85 (0.5-1.4) .5
Cytogenetic analysis (Ph + others versus Ph only) 0.9 (0.5-1.4) .6
Age at HSCT (>40 versus #40) 2.2 (1.4-3.5) .001
Disease status at HSCT (CR2, Active
disease versus CR1)
2.1 (1.1-4.3) .03
2.2 (1.3-3.6) .003
HSCT conditioning (TBI versus non-TBI) 0.6 (0.4-0.9) .02
Year of HSCT ($2000 versus <2000) 0.4 (0.3-0.7) <.001
Allotype (MUD, AgMM versus MRD) 1.01 (0.6-1.6) .9
0.8 (0.4-1.7) .6
TKI pre-HSCT* (yes versus no) 0.8 (0.4-1.6) .6
MRD present (yes versus no) 0.7 (0.4-1.4) .3
Acute GVHD 2-4 (time-dependent variable) 1.3 (0.8-2.1) .9
TKI post-HSCT landmark analysis starting
at 6 months
0.6 (0.2-1.4) .2
TKI post-HSCT (CR1 patients) landmark
analysis starting at 6 months
0.4 (0.1-1.3) .1
CI indicates confidence interval; CR, complete remission; HR, hazard ratio; M
*Evaluable in recipients of transplant after 1999.maintained molecular complete remission (continued
complete remission n 5 23, complete remission
n 5 32). Thirty-three patients relapsed at a median
of 5 months following HSCT (range: 1-39 months).
PFS rates at 2 and 5 years were 36% and 31%, respec-
tively, for the entire group; among patients trans-
planted in first remission, PFS at 5 years was 42%
compared with 9% for patients transplanted in second
remission and 16% for patients transplanted with
active disease at time of HSCT, first remission versus
others, P5 .006. The variables analyzed in a univariate
analysis for relapse are listed in Table 2. Age
.40 years, transplant year before 2000, disease stage
other than first remission at time of HSCT, and
non–TBI-based HSCT conditioning were associated
with significantly increased rates of relapse in a univar-
iate analysis; age, transplant year, and disease stage re-
tained significance in a multivariate model (Table 3).
Of note, the use of pre- or post-HSCT TKI therapy
did not have an impact on PFS (Table 4, Figure 2).
The presence of minimal residual disease (MRD)
pre-HSCT was also not a significant predictor for
PFS.
Overall Survival
The median follow-up among 75 survivors was
5 years (range: 1.1-20.4 years). OS rates at 2 and 5 years
were 44% and 33%, respectively, for the entire group;
among patients transplanted in first remission, OS at
5 years was 43% compared with 9% for patients trans-
planted in second remission and 16% for patients
transplanted with active disease at time of HSCT, first
remission versus others, P5 .002 (Figure 1). Similar to
the analyses for PFS, older age, transplant in the
1990s, advanced disease stage at time of HSCT, and
non–TBI-containing transplant conditioning regi-
mens predicted for worse OS in a univariate analysisand NRM at 5 Years Post-HSCT
Progression-Free Survival Nonrelapse Mortality
HR (95% CI) P HR (95% CI) P
0.8 (0.5-1.3) 0.4 0.9 (0.5-1.7) .8
0.9 (0.5-1.4) .5 0.9 (0.5-1.7) .7
2.1 (1.3-3.3) .001 2.6 (1.4-4.7) .003
1.9 (0.9-3.8) .07 2.0 (0.8-4.9) .1
2.4 (1.4-3.9) .001 2.1 (1.1-4.2) .03
0.6 (0.4-0.9) .02 0.6 (0.3-1.02) .06
0.4 (0.3-0.7) <.001 0.4 (0.2-0.8) .01
0.9 (0.6-1.6) .9 1.4 (0.7-2.6) .3
0.8 (0.4-1.8) .6 1.1 (0.4-2.8) .9
0.8 (0.4-1.6) .5 1.1 (0.4-2.8) .9
0.7 (0.4-1.4) .4 0.8 (0.3-1.8) .5
1.2 (0.7-1.9) .6 2.6 (1.4-4.8) .004
0.8 (0.3-2.2) .7 0.8 (0.2-2.6) .7
0.6 (0.1-2.6) .5 0.6 (0.1-3.6) .6
RD, matched related donor; MUD, matched unrelated donor.
Table 3. Multivariate Analysis of Significant Predictors for OS, PFS, and NRM at 5 Years Post-HSCT
Variable
Overall Survival Progression-Free Survival Nonrelapse Mortality
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age at HSCT (>40 versus #40) 2.5 (1.6-3.9) <.001 2.3 (1.4-3.6) <.001 3.0 (1.6-5.7) .001
Disease status at HSCT (CR1 versus others) 0.5 (0.3-0.8) .002 0.5 (0.3-0.8) .006 0.4 (0.2-0.8) .01
Year of HSCT ($2000 versus <2000) 0.4 (0.3-0.7) .001 0.4 (0.3-0.7) .001 0.5 (0.3-1.03) .06
Acute GVHD 2-4 (time-dependent variable) 1.88 (1.03-3.41) .04 2.05 (1.16-3.64) .01 2.6 (1.4-4.8) .004
CI indicates confidence interval; CR, complete remission; HR, hazard ratio.
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stage retaining significance in a multivariate model
(Table 3). Again, TKI use andminimal residual disease
(MRD) status did not significantly impact OS.Treatment Toxicity
Among 60 evaluable patients who received
a matched related transplant, the cumulative incidence
of aGVHD grades II to IV and III to IV were 30% and
11%, respectively. Among 38 evaluable patients who
received a matched unrelated transplant, the cumula-
tive incidence of aGVHD grades II to IV and III to
IV were 55% and 20%, respectively. Among 9 evalu-
able patients who received a double cord blood trans-
plant, the cumulative incidence of aGVHD grades II
to IV and III to IV were 55% and 11%, respectively.
The cumulative incidence of grades 2 to 4 aGVHD
was associated with a significantly higher rate of
NRM both in the univariate and multivariate analyses
(Tables 2 and 3). Neither the use of TKI pre- nor post-
HSCT had any impact on the development of
aGVHD or cGVHD.
The cumulative incidence of NRM at 100 days,
and 2 and 5 years was 17%, 35%, and 39%, respec-
tively. The NRM was significantly higher for patients
transplanted in advanced disease versus in first remis-
sion, 48% versus 33%, P5 .01. Disease recurrence ac-
counted for 32 of 75 deaths. The remaining deaths
were because of the following: graft rejection (n 5
1), infection (n 5 10), GVHD (n 5 26), hemorrhage
(n 5 2), and multiorgan failure (n 5 4).Salvage Therapies after Relapse
Patients died at a median of 4.2 months following
relapse (range: 0-27.4). No patients survived relapse.
Four patients received a second transplant with
a median survival of 12.5 months following second
HSCT (range: 5.6-27.4 months); 3 of these patients
had a sustained remission but died of nonrelapse toxi-Table 4. The Impact of TKI Maintenance on Progression Based on
Progressed/+MRD Pre-HSCT (%) Progr
TKI maintenance 5/16 (31)
No TKI 11/35 (31)city. Two patients received a single donor leukocyte
infusion following transplantation with no response.DISCUSSION
Although the introduction of TKI into the upfront
therapy for Ph1 ALL has clearly demonstrated im-
proved response rates and superior OS, the impact for
TKI therapy specifically on transplant outcomes is less
clear, beyond the observation that more patients will be
able to receive a transplant in first remission. To our
knowledge, this is the largest published series of trans-
planted patients with Ph1 ALL who received TKI
therapy before and after HSCT. Similar to earlier re-
ports [19-21,31-33], we did not find increased toxicity
with TKI use peritransplantation (Tables 2 and 3);
specifically, no excess cardiac toxicities were noted,
despite concerns regarding cardiac toxicity that were
reported in patients with advanced chronic
myelogenous leukemia receiving imatinib [34,35].
Fluid retention and cytopenias were the most
commonly observed toxicities, and were responsive to
TKI dose reductions. Importantly, it was feasible to
begin TKI maintenance at a median of 2 months
following HSCT, before the median time to relapse
for patients with advanced ALL.
Six patients had presence of MRD at 30 days fol-
lowing SCT, and 3 became MRD negative after TKI
maintenance initiation. This 50% molecular response
rate is comparable to reported results. Wassmann and
colleagues [33] reported on 27 patients with Ph1 ALL
who received imatinib upon detection ofMRD follow-
ing HSCT. Fourteen patients became MRD negative
and remained in remission for the duration of imatinib
therapy; 3 patients relapsed after imatinib was discon-
tinued. Similarly, in a study reported by Chen and
colleagues [32], among 11 patients with Ph1 ALL
and persistent MRD following SCT, 7 became MRD
negative following imatinib initiation post-SCT.
However, when we compared our molecular responsePresence of Minimal Residual Disease
essed/+MRD +1 Month (%) Progressed/+MRD +3 Months (%)
3/6 (50) 4/7 (57)
4/9 (44) 5/9 (56)
Figure 1. OS by disease status at time of HSCT. OS rates at 5 years for
patients in CR1, CR2, and active disease were 43%, 9%, and 16%, respec-
tively.
590 Biol Blood Marrow Transplant 18:584-592, 2012P. Kebriaei et al.rate with our patients who did not receive TKI main-
tenance, a similar number of patients eventually
became MRD negative (4 of 11). Furthermore, when
we looked at the rate of progression for TKI mainte-
nance versus no TKI in patients with persistent
MRD before and after transplantation, we found no
difference between the 2 groups (Table 4). Finally,
we saw no difference in PFS for patients who received
TKI maintenance (Figure 2), with no difference in re-
sults when the analysis was restricted to first remission
patients (data not shown). Similar findings were noted
in a Children’s Oncology Group study, with no differ-
ence in EFS for 6 months of TKI maintenance follow-
ing HSCT compared with historical transplant
outcomes [31].
Of note, the presence of MRD pretransplantation
had no significant impact on outcomes in univariate
and multivariate analyses (Tables 2 and 3). Additional
analyses restricted to remission patients only or
patients not receiving TKI maintenance again foundFigure 2. PFS. PFS by TKI maintenance post-HSCT using a landmark
analysis at 6 months.no impact for MRD pretransplantation (data not
shown). We had too few patients to assess for the
impact of persistent MRD posttransplantation. This
is in contrast to earlier reports for MRD monitoring
in Ph1 ALL patients, which showed that the
presence of MRD pretransplantation was predictive
for relapse [33,36-38]. Of note in the study by Patel
and colleagues [39], only one-half of the patients were
consolidated with allogeneic HSCT. In the largest se-
ries of MRD assessment, on 161 B-lineage, Ph-
negative (Ph2) patients uniformly treated on the
UKALL XII/ECOG 2993, the presence of MRD fol-
lowing induction, consolidation, and before auologous
HSCT was predictive for relapse, but importantly not
before allogeneic HSCT in first remission patients,
suggesting that perhaps a graft-versus-leukemia effect
may affect MRD at this time point in treatment. Simi-
larly, in another small series of both Ph1 and
Ph2 patients, the presence of MRD was significant
for relapse at day 100 following induction therapy,
but not before allogeneic HSCT [40].
Disease stage at time of HSCT, age, and decade of
transplantation were noted to have a significant impact
on OS, PFS, and NRM in multivariate analysis. Dis-
ease stage at time of HSCT has consistently been
noted to be 1 of the strongest predictors for outcome
in patients with Ph1 ALL[41-45]. Similar to other
reports, older age predicted for worse outcome [14],
although age .40 years predicted for worse PFS,
NRM and OS in our study, although it had no impact
on relapse rates in the UKALL XII/ECOG2993 trial
[46]. Finally, in contrast to the report by Laport and
colleagues [41], we found a significant improvement
for transplantation in the current versus prior decade,
presumably because of modifications in the induction
and salvage therapies before transplantation, the trans-
plantation conditioning regimens, and overall im-
proved supportive care.
In conclusion, we found no apparent benefit for the
use of peritransplantation TKI. Our observations are
limited because of the retrospective nature of our anal-
yses, the heterogeneity in transplant conditioning reg-
imens, allotype, and HSCT cell source, as well as the
small sample size. Still, the observation for no im-
provement in PFS with TKI maintenance needs to
be emphasized, and underscores the need for further
investigation through randomized, prospective stud-
ies. Although we, and others, have demonstrated the
immediate feasibility and relative safety of TKI main-
tenance, the longer-term effects on immunomodula-
tion and graft-versus-leukemia have not been well
studied. For example, serial monitoring of T cell sub-
sets from patients with Ph1 ALL on chronic imatinib
therapy showed no deficit in T lymphocyte prolifera-
tion and activity [47]. However, ex vivo studies demon-
strated profound inhibition of T cell activity, including
inhibition of T regulatory cell function, with dasatnib
Biol Blood Marrow Transplant 18:584-592, 2012 591Allogeneic HSCT for Ph+ ALLuse [48]. Thus, the benefit for TKI maintenance fol-
lowing allogeneic HSCT remains under investigation.ACKNOWLEDGMENTS
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